(Z)-methyl 5-methyl-3-cyanohex-2-enoate | 1239326-95-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-methyl 5-methyl-3-cyanohex-2-enoate
• 英文别名: methyl (Z)-3-cyano-5-methylhex-2-enoate
• CAS: 1239326-95-4
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: GEMUYRCTNJLMSN-YVMONPNESA-N

物化性质

• 沸点：
  250.1±23.0 °C(Predicted)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-methyl 5-methyl-3-cyanohex-2-enoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 以93%的产率得到3-cyano-5-methylhexanoic acid methyl ester
  参考文献：
  名称：

  Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases

  摘要：

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.

  DOI：

  10.1021/jo302484p
• 作为产物：
  描述：

  4-甲基-2-氧代戊腈 在 正丁基锂 、 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 18.5h， 生成 (Z)-methyl 5-methyl-3-cyanohex-2-enoate
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF ( S ) - 3 - CYANO - 5 - METHYLHEXANOIC ACID DERIVATIVES ADN OF PREGABALIN
  [FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'ACIDE (S)-3-CYANO-5-MÉTHYLHEXANOÏQUE ET DE PRÉGABALINE

  摘要：

  这项发明提供了一种利用酶催化还原公式(I)化合物的制备过程，其中所述化合物为公式(lla)或llb)的化合物。公式(I)的化合物可用于制备普拉巴林。

  公开号：

  WO2012025861A1

文献信息

• Nickel/Lewis Acid-Catalyzed Cyanoesterification and Cyanocarbamoylation of Alkynes
  作者：Yasuhiro Hirata、Akira Yada、Eiji Morita、Yoshiaki Nakao、Tamejiro Hiyama、Masato Ohashi、Sensuke Ogoshi

  DOI：10.1021/ja102346v

  日期：2010.7.28

  nickel/Lewis acid (LA) cooperative catalysis to give beta-cyano-substituted acrylates and acrylamides, respectively, in highly stereoselective and regioselective manners. The resulting adducts serve as versatile synthetic building blocks through chemoselective transformations of the ester, amide, and cyano groups as demonstrated by the synthesis of typical structures of beta-cyano ester, beta-amino

  发现氰基甲酸酯和氰基甲酰胺通过镍/路易斯酸 (LA) 协同催化在炔烃上加成，分别以高度立体选择性和区域选择性的方式生成 β-氰基取代的丙烯酸酯和丙烯酰胺。由此产生的加合物通过酯、酰胺和氰基的化学选择性转化作为通用的合成构件，如β-氰基酯、β-氨基腈、γ-内酰胺、双取代马来酸酐和γ的典型结构的合成所证明的-氨基丁酸。另一方面，发现氰基甲酸酯硫酯和苯甲酰氰的相关反应在钯/LA 催化剂存在下通过脱羰在炔烃上加成。
• [EN] PROCESS FOR THE PREPARATION OF ( S ) - 3 - CYANO - 5 - METHYLHEXANOIC ACID DERIVATIVES ADN OF PREGABALIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS D'ACIDE (S)-3-CYANO-5-MÉTHYLHEXANOÏQUE ET DE PRÉGABALINE
  申请人：PFIZER MFG IRELAND

  公开号：WO2012025861A1

  公开（公告）日：2012-03-01

  The invention provides a process for the manufacture of a compound of formula (I) using an enzyme catalysed reduction of a compound of formula (lla) or llb). Compounds of formula (I) are useful for preparing pregabalin.

  这项发明提供了一种利用酶催化还原公式(I)化合物的制备过程，其中所述化合物为公式(lla)或llb)的化合物。公式(I)的化合物可用于制备普拉巴林。
• Chemoenzymatic Asymmetric Synthesis of Pregabalin Precursors via Asymmetric Bioreduction of β-Cyanoacrylate Esters Using Ene-Reductases
  作者：Christoph K. Winkler、Dorina Clay、Simon Davies、Pat O’Neill、Paul McDaid、Sebastien Debarge、Jeremy Steflik、Mike Karmilowicz、John W. Wong、Kurt Faber

  DOI：10.1021/jo302484p

  日期：2013.2.15

  The asymmetric bioreduction of a library of beta-cyanoacrylate esters using ene-reductases was studied with the aim to provide a biocatalytic route to precursors for GABA analogues, such as pregabalin. The stereochemical outcome could be controlled by substrate-engineering through size-variation of the ester moiety and by employing stereochemically pure (E)- or (Z)-isomers, which allowed to access both enantiomers of each product in up to quantitative conversion in enantiomerically pure form. In addition, stereoselectivities and conversions could be improved by mutant variants of OPR1, and the utility of the system was demonstrated by preparative-scale applications.